Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey

INTRODUCTION: Patients with cancer and hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are underrepresented in several clinical trials testing immune checkpoint inhibitors (ICIs). Consequently, safety and efficacy of ICI therapy in this population have not been completely defined. We ai...

Descripción completa

Detalles Bibliográficos
Autores principales: Tagliamento, Marco, Remon, Jordi, Giaj Levra, Matteo, De Maria, Andrea, Bironzo, Paolo, Besse, Benjamin, Novello, Silvia, Mezquita, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853354/
https://www.ncbi.nlm.nih.gov/pubmed/36687558
http://dx.doi.org/10.1016/j.jtocrr.2022.100446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853354/
https://www.ncbi.nlm.nih.gov/pubmed/36687558
http://dx.doi.org/10.1016/j.jtocrr.2022.100446

Ejemplares similares